Treatment-resistant depression and intranasal esketamine: Spanish clinical consensus on practical aspects
The European Journal of Psychiatry May 2, 2025 Josep Antoni Ramos‐quiroga, Fernando Mora, Silvia Arostegui et al. 4 citations
Pharmacological management of major depressive disorder has traditionally relied on antidepressants targeting the monoaminergic pathway. Treatment-resistant depression (TRD) patients have been frequently excluded from registrational trials, resulting in a lack of clear clinical recommendations for an optimised management. In recent years, treatments based on other mechanisms of action have been...
DOI: 10.1016/j.ejpsy.2025.100313 (opens in new tab)
Treatment-resistant depression
Major depressive disorder
Nasal administration
Depression economics
+2